These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 21528424

  • 1. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs.
    Mori S.
    Mod Rheumatol; 2011 Dec; 21(6):621-7. PubMed ID: 21528424
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V, Viganò M, Batticciotto A, Lampertico P, Marchesoni A, Gibertini P, Pellerito R, Rovera G, Caporali R, Todoerti M, Covelli M, Notarnicola A, Atzeni F, Sarzi-Puttini P.
    J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
    [Abstract] [Full Text] [Related]

  • 4. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
    Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S.
    Int J Rheum Dis; 2016 May; 19(5):470-5. PubMed ID: 24698305
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
    Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N.
    J Gastroenterol; 2011 Apr; 46(4):556-64. PubMed ID: 21246383
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M, Winthrop K, Takeuchi T, Hsieh TY, Chen YM, Smolen JS, Burmester G, Walls C, Wu WS, Dickson C, Liao R, Genovese MC.
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
    [Abstract] [Full Text] [Related]

  • 8. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
    Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS.
    Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
    [Abstract] [Full Text] [Related]

  • 9. Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience.
    Ahn SS, Jung SM, Song JJ, Park YB, Park JY, Lee SW.
    Yonsei Med J; 2018 May; 59(3):452-456. PubMed ID: 29611409
    [Abstract] [Full Text] [Related]

  • 10. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib.
    Wang ST, Tseng CW, Hsu CW, Tung CH, Huang KY, Lu MC, Lai NS.
    Int J Rheum Dis; 2021 Nov; 24(11):1362-1369. PubMed ID: 34506078
    [Abstract] [Full Text] [Related]

  • 11. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
    Watanabe T, Fukae J, Fukaya S, Sawamukai N, Isobe M, Matsuhashi M, Shimizu M, Akikawa K, Tanimura K, Atsumi T, Koike T.
    Int J Rheum Dis; 2019 Apr; 22(4):574-582. PubMed ID: 30338649
    [Abstract] [Full Text] [Related]

  • 12. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
    Lee YH, Bae SC, Song GG.
    Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
    [Abstract] [Full Text] [Related]

  • 13. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital.
    Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, Handa Y, Hayashi M, Koyama Y, Arii K, Kitaori T, Hagiyama H, Urushidani Y, Yamasaki T, Ikeno Y, Suzuki T, Omoto A, Sugitani T, Morita S, Inokuma S.
    Arthritis Res Ther; 2019 Nov 28; 21(1):255. PubMed ID: 31779676
    [Abstract] [Full Text] [Related]

  • 14. Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients.
    Schwaneck EC, Krone M, Kreissl-Kemmer S, Weißbrich B, Weiss J, Tony HP, Gadeholt O, Schmalzing M, Geier A.
    Clin Rheumatol; 2018 Nov 28; 37(11):2963-2970. PubMed ID: 30238380
    [Abstract] [Full Text] [Related]

  • 15. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.
    Chiu YM, Lai MS, Chan KA.
    PLoS One; 2018 Nov 28; 13(4):e0196210. PubMed ID: 29694398
    [Abstract] [Full Text] [Related]

  • 16. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg-/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis.
    Kuo MH, Tseng CW, Lee CH, Tung CH, Tseng KC, Lai NS.
    Sci Rep; 2020 Feb 12; 10(1):2456. PubMed ID: 32051458
    [Abstract] [Full Text] [Related]

  • 17. [Investigation of the risk of hepatitis B virus reactivation in arthritis patients undergoing anti-tumour necrosis factor alpha therapy].
    Jin D, Tie N, Liu J, Zhao L, Hao D, Zhao Y.
    Zhonghua Nei Ke Za Zhi; 2015 Apr 12; 54(4):313-6. PubMed ID: 26268059
    [Abstract] [Full Text] [Related]

  • 18. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
    Chen LF, Mo YQ, Jing J, Ma JD, Zheng DH, Dai L.
    Int J Rheum Dis; 2017 Jul 12; 20(7):859-869. PubMed ID: 28160426
    [Abstract] [Full Text] [Related]

  • 19. HBV reactivation in HBsAg-/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs.
    Kuo MH, Tseng CW, Ko PH, Wang ST, Lu MC, Tung CH, Tseng KC, Huang KY, Lee CH, Lai NS.
    Liver Int; 2024 Feb 12; 44(2):497-507. PubMed ID: 38010984
    [Abstract] [Full Text] [Related]

  • 20. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.
    Giardina AR, Ferraro D, Ciccia F, Ferrante A, Di Stefano R, Craxì A, Triolo G.
    Clin Exp Rheumatol; 2013 Feb 12; 31(1):25-30. PubMed ID: 22935442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.